News

Hysingla ER is a once-daily, single-entity medication formulated using the company’s extended-release solid oral platform, RESISTEC, which uses a combination of polymer and processing that confers tablet hardness

Dupilumab is indicated for AD patients who are not adequately controlled with topical prescription therapy and/or for whom these treatments are not appropriate. It is an investigational therapy

The company, which is focused on research, development and production of pharmaceutical, nutraceutical and cosmetic products, has executed an option agreement for a land purchase of a 5,328m²

The kit has been designed for use in imaging and intraoperative detection of sentinel lymph nodes draining a primary tumor in adult patients with breast cancer, melanoma or

Started in late July 2014, the Phase IIa trial is being conducted under an investigational new drug (IND) application filed by the company’s licensor, the Blanchette Rockefeller Neuroscience

As part of the deal, the two parties will jointly work on projects, based on an overarching research plan, in the HBV and liver cancer fields with funding

Produced using proprietary technology, Nagase’s unnatural amino acids are unique chiral building blocks for small molecule and peptide synthesis and can help overcome challenges in designing next-generation drug

Published in the November edition of the Drug Information Association’s Therapeutic Innovation & Regulatory Science (TIRS) journal, the results of the analysis support the TransCelerate-proposed methodology for risk-based

Biologic medicines are produced in living cells and the new Tuas facility encompasses multiple technologies to enable greater speed, productivity and flexibility in commercial-scale manufacturing. Built in less